Skip to main content
. 2015 Sep;185(9):2534–2549. doi: 10.1016/j.ajpath.2015.04.029

Figure 3.

Figure 3

Systemic administration of the CCR3 antagonist GW766994X attenuates laser-induced and spontaneous choroidal neovascularization (CNV) in mice. A: Representative fluorescein angiography (FFA) images from all treatment groups at the 2-week time point. B: Systemic GW766994X dose-dependently suppresses laser-induced CNV. Animals were dosed once daily (QD) or twice daily (BID) orally 1 day before laser injury, with treatment continuing for 14 days. C: Representative CNV staining (fluorescein isothiocyanate-IB4, white vessels) of eye cups (retina removed; optic nerve at center of image) from JR5558 mice shows reduction in CNV in GW766994X-treated mice. Images are from two individual animals from each treatment group from the experiment shown in D and E. D and E: Systemic i.p. dosing with CCR3 antagonist GW766994X significantly suppresses spontaneous CNV development in JR5558 mice. Both the average CNV area per eye (D) and number of lesions per eye (E) are reduced by systemic GW766994X treatment in a dose-dependent manner. Data are expressed as means ± SEM (E). n = 76 to 78 individual laser burns per group (B); n = 8 to 10 eyes per group (E). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 versus vehicle control. Scale bar = 1 mm (C).